BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 34551653)

  • 1. Retinal optical coherence tomography and magnetic resonance imaging in neuromyelitis optica spectrum disorders and MOG-antibody associated disorders: an updated review.
    Lin TY; Chien C; Lu A; Paul F; Zimmermann HG
    Expert Rev Neurother; 2021 Oct; 21(10):1101-1123. PubMed ID: 34551653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis.
    Jarius S; Aktas O; Ayzenberg I; Bellmann-Strobl J; Berthele A; Giglhuber K; Häußler V; Havla J; Hellwig K; Hümmert MW; Kleiter I; Klotz L; Krumbholz M; Kümpfel T; Paul F; Ringelstein M; Ruprecht K; Senel M; Stellmann JP; Bergh FT; Tumani H; Wildemann B; Trebst C;
    J Neurol; 2023 Jul; 270(7):3341-3368. PubMed ID: 37022481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optic chiasm involvement in multiple sclerosis, aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein-associated disease.
    Bianchi A; Cortese R; Prados F; Tur C; Kanber B; Yiannakas MC; Samson R; De Angelis F; Magnollay L; Jacob A; Brownlee W; Trip A; Nicholas R; Hacohen Y; Barkhof F; Ciccarelli O; Toosy AT
    Mult Scler; 2024 May; 30(6):674-686. PubMed ID: 38646958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Follow-up of retinal thickness and optic MRI after optic neuritis in anti-MOG antibody-associated disease and anti-AQP4 antibody-positive NMOSD.
    Akaishi T; Himori N; Takeshita T; Misu T; Takahashi T; Takai Y; Nishiyama S; Kaneko K; Fujimori J; Ishii T; Aoki M; Fujihara K; Nakazawa T; Nakashima I
    J Neurol Sci; 2022 Jun; 437():120269. PubMed ID: 35483239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
    Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
    J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
    Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
    Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI characteristics of MOG-Ab associated disease in adults: An update.
    Shor N; Deschamps R; Cobo Calvo A; Maillart E; Zephir H; Ciron J; Papeix C; Durand-Dubief F; Ruet A; Ayrignac X; Cohen M; Deiva K; Laplaud D; Bourre B; Audoin B; Collongues N; Vukusic S; Cotton F; Marignier R;
    Rev Neurol (Paris); 2021; 177(1-2):39-50. PubMed ID: 33046261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging.
    Cortese R; Prados Carrasco F; Tur C; Bianchi A; Brownlee W; De Angelis F; De La Paz I; Grussu F; Haider L; Jacob A; Kanber B; Magnollay L; Nicholas RS; Trip A; Yiannakas M; Toosy AT; Hacohen Y; Barkhof F; Ciccarelli O
    Neurology; 2023 Jan; 100(3):e308-e323. PubMed ID: 36192175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chiasmatic lesions on conventional magnetic resonance imaging during the first event of optic neuritis in patients with neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein-associated disease in a Latin American cohort.
    Carnero Contentti E; López PA; Criniti J; Pettinicchi JP; Cristiano E; Patrucco L; Bribiesca Contreras E; Gómez-Figueroa E; Flores-Rivera J; Correa-Díaz EP; Toral Granda AM; Ortiz Yepez MA; Gualotuña Pachacama WA; Piedra Andrade JS; Galleguillos L; Tkachuk V; Nadur D; Daccach Marques V; Soto de Castillo I; Casas M; Cohen L; Alonso R; Caride A; Lana-Peixoto M; Rojas JI
    Eur J Neurol; 2022 Mar; 29(3):802-809. PubMed ID: 34799965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retinal structural and microvascular changes in myelin oligodendrocyte glycoprotein antibody disease and neuromyelitis optica spectrum disorder: An OCT/OCTA study.
    Lang Y; Kwapong WR; Kong L; Shi Z; Wang X; Du Q; Wu B; Zhou H
    Front Immunol; 2023; 14():1029124. PubMed ID: 36793713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort.
    Dauby S; Dive D; Lutteri L; Andris C; Hansen I; Maquet P; Lommers E
    Acta Neurol Belg; 2022 Feb; 122(1):135-144. PubMed ID: 34097296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brighter spotty lesions on spinal MRI help differentiate AQP4 antibody-positive NMOSD from MOGAD.
    Hyun JW; Lee HL; Park J; Kim J; Min JH; Kim BJ; Kim SW; Shin HY; Huh SY; Kim W; Seo JW; Kim KH; Kim SH; Kim HJ
    Mult Scler; 2022 May; 28(6):989-992. PubMed ID: 34865555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central vein sign and other radiographic features distinguishing myelin oligodendrocyte glycoprotein antibody disease from multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica.
    Ciotti JR; Eby NS; Brier MR; Wu GF; Chahin S; Cross AH; Naismith RT
    Mult Scler; 2022 Jan; 28(1):49-60. PubMed ID: 33870786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration.
    Havla J; Kümpfel T; Schinner R; Spadaro M; Schuh E; Meinl E; Hohlfeld R; Outteryck O
    J Neurol; 2017 Jan; 264(1):139-151. PubMed ID: 27844165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRI to differentiate multiple sclerosis, neuromyelitis optica, and myelin oligodendrocyte glycoprotein antibody disease.
    Carnero Contentti E; Okuda DT; Rojas JI; Chien C; Paul F; Alonso R
    J Neuroimaging; 2023; 33(5):688-702. PubMed ID: 37322542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and neuroimaging findings in MOGAD-MRI and OCT.
    Bartels F; Lu A; Oertel FC; Finke C; Paul F; Chien C
    Clin Exp Immunol; 2021 Dec; 206(3):266-281. PubMed ID: 34152000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripapillary hyper-reflective ovoid mass-like structures (PHOMS) in AQP4-IgG-positive neuromyelitis optica spectrum disease (NMOSD) and MOG-IgG-associated disease (MOGAD).
    Gernert JA; Wicklein R; Hemmer B; Kümpfel T; Knier B; Havla J
    J Neurol; 2023 Feb; 270(2):1135-1140. PubMed ID: 36245037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuromyelitis Optica Spectrum Disorders.
    Akaishi T; Nakashima I; Sato DK; Takahashi T; Fujihara K
    Neuroimaging Clin N Am; 2017 May; 27(2):251-265. PubMed ID: 28391784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis.
    Messina S; Mariano R; Roca-Fernandez A; Cavey A; Jurynczyk M; Leite MI; Calabrese M; Jenkinson M; Palace J
    Mult Scler; 2022 Feb; 28(2):217-227. PubMed ID: 34048323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
    J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.